CL2017001563A1 - Formulación de virus de herpes simple estable congelada - Google Patents

Formulación de virus de herpes simple estable congelada

Info

Publication number
CL2017001563A1
CL2017001563A1 CL2017001563A CL2017001563A CL2017001563A1 CL 2017001563 A1 CL2017001563 A1 CL 2017001563A1 CL 2017001563 A CL2017001563 A CL 2017001563A CL 2017001563 A CL2017001563 A CL 2017001563A CL 2017001563 A1 CL2017001563 A1 CL 2017001563A1
Authority
CL
Chile
Prior art keywords
herpes simplex
simplex virus
virus formulation
frozen
stable
Prior art date
Application number
CL2017001563A
Other languages
English (en)
Inventor
Jennifer R Litowski
Christine Claudia Siska
Bruce Arthur Kerwin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2017001563A1 publication Critical patent/CL2017001563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>SE DESCRIBE UNA COMPOSICIÓN DE VIRUS VIVO QUE SE MANTIENE NO INFECTIVA Y PROPORCIONA ESTABILIDAD MEJORADA DEL VIRUS DURANTE UNO O MÁS CICLOS DE CONGELADO/DESCONGELADO Y/O DURANTE EL ALMACENADO A LARGO PLAZO EN UN ESTADO LÍQUIDO A TEMPERATURAS EN EL INTERVALO DESDE APENAS ARRIBA DE LA CONGELACIÓN HASTA TEMPERATURAS AMBIENTE.</p>
CL2017001563A 2014-12-18 2017-06-15 Formulación de virus de herpes simple estable congelada CL2017001563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093663P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
CL2017001563A1 true CL2017001563A1 (es) 2018-01-26

Family

ID=55229814

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001563A CL2017001563A1 (es) 2014-12-18 2017-06-15 Formulación de virus de herpes simple estable congelada

Country Status (18)

Country Link
US (2) US20170360857A1 (es)
EP (1) EP3234114B9 (es)
JP (2) JP6975041B2 (es)
KR (2) KR102549746B1 (es)
CN (1) CN107580626A (es)
AU (3) AU2015362687B2 (es)
BR (1) BR112017013009A2 (es)
CA (1) CA2971201A1 (es)
CL (1) CL2017001563A1 (es)
CO (1) CO2017007086A2 (es)
EA (1) EA201791382A1 (es)
ES (1) ES2948037T3 (es)
IL (3) IL308119B2 (es)
MA (1) MA40948A (es)
MX (2) MX2017008013A (es)
SG (1) SG11201704975SA (es)
WO (1) WO2016100364A1 (es)
ZA (1) ZA201704695B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2861450T3 (es) * 2015-07-20 2021-10-06 Virttu Biologics Ltd Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer
US12310999B2 (en) 2017-04-28 2025-05-27 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
WO2019213509A1 (en) * 2018-05-03 2019-11-07 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
CN109161562A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法
CA3124690A1 (en) * 2018-12-27 2020-07-02 Amgen Inc. Lyophilized virus formulations
JP2023540427A (ja) * 2020-07-07 2023-09-25 オリエンジーン バイオテクノロジー リミテッド Ｈｓｖ－１遺伝子編集のためのガイドｒｎａおよびその方法
WO2022158097A1 (ja) * 2021-01-19 2022-07-28 新田ゼラチン株式会社 ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS FOR TREATING NEOPLASTIC DISEASES
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
CA2441663C (en) 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
EP2940129B1 (en) * 2007-04-06 2020-05-06 Takeda Vaccines, Inc. Methods and compositions for live attenuated viruses
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN101926990A (zh) * 2010-09-21 2010-12-29 中山大学 肿大细胞病毒vsocs基因缺失减毒活疫苗及其制备方法和应用
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
WO2013106398A1 (en) * 2012-01-09 2013-07-18 Sanofi Pasteur Biologics, Llc Purification of herpes virus
WO2013177172A2 (en) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
JP6457940B2 (ja) * 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法

Also Published As

Publication number Publication date
AU2015362687B2 (en) 2021-12-09
IL300202B2 (en) 2024-04-01
IL308119B2 (en) 2025-11-01
EP3234114B1 (en) 2023-04-12
AU2025201675A1 (en) 2025-03-27
IL308119B1 (en) 2025-07-01
IL252942A0 (en) 2017-08-31
SG11201704975SA (en) 2017-07-28
JP2018502078A (ja) 2018-01-25
EP3234114A1 (en) 2017-10-25
AU2015362687A1 (en) 2017-07-06
MA40948A (fr) 2017-10-25
MX2017008013A (es) 2018-03-06
IL300202B1 (en) 2023-12-01
KR20230107375A (ko) 2023-07-14
HK1245823A1 (en) 2018-08-31
AU2022201523C1 (en) 2025-10-02
ES2948037T3 (es) 2023-08-30
US20210052680A1 (en) 2021-02-25
WO2016100364A1 (en) 2016-06-23
EP3234114B9 (en) 2023-06-14
CO2017007086A2 (es) 2017-10-10
CA2971201A1 (en) 2016-06-23
CN107580626A (zh) 2018-01-12
US20170360857A1 (en) 2017-12-21
AU2022201523B2 (en) 2024-12-12
JP2021072795A (ja) 2021-05-13
ZA201704695B (en) 2023-12-20
JP6975041B2 (ja) 2021-12-01
BR112017013009A2 (pt) 2018-06-26
IL300202A (en) 2023-03-01
MX2023012564A (es) 2023-11-08
EA201791382A1 (ru) 2017-10-31
KR102549746B1 (ko) 2023-07-03
AU2022201523A1 (en) 2022-03-24
IL308119A (en) 2023-12-01
KR20170095270A (ko) 2017-08-22

Similar Documents

Publication Publication Date Title
CL2017001563A1 (es) Formulación de virus de herpes simple estable congelada
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CO2019001448A2 (es) Composiciones y métodos para estabilizar flavivirus con formulaciones mejoradas
CU20180154A7 (es) Formulación farmacéutica líquida estable
CL2016003125A1 (es) Dispositivo de conexión de los elementos estructurales de nervaduras y estructuras reticulares
EP3332189A4 (en) ADIABATIC VACUUM BODY AND REFRIGERATOR
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
AR094348A1 (es) Diferenciación de células madre embrionarias humanas a células pancreáticas endocrinas con el uso de reguladores hb9
PL3232777T3 (pl) Przechowywanie i transport próbki biologicznej ex vivo obejmujące zastosowanie ultradźwięków
MX2016011176A (es) Polipeptidos fhbp meningococicos modificados.
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR098596A1 (es) Formulaciones listas de fertilizante líquido de bifentrina
EA201692236A1 (ru) Небулайзер и контейнер
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
EP3372921A4 (en) EVAPORATOR AND REFRIGERATOR WITH IT
IL249376B (en) Proliferation and transplantation of stem cells using notch1 and/or notch2 agonists
MX377168B (es) Sistemas generadores de impulso electrico que utilizan acoplamiento capacitivo.
LT3419595T (lt) Stabili skysta gonadotropino kompozicija
AR101332A1 (es) Búsqueda de forma mediante cuantificador de vectores pirámide
CL2017001834A1 (es) Contenedor de palé que tiene un forro interior
IL252613A0 (en) Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
EA201692239A1 (ru) Небулайзер
CL2016001801A1 (es) Proceso para la reconstitución de una forma sólida de una composición farmacéutica.
EP3435003A4 (en) EVAPORATOR AND REFRIGERATOR WITH IT
TWD168034S (zh) 凍結保存容器